BIOMAT Database Logo BIOMAT Database Logo

MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS. 2019

V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
Tbilisi State Medical University, Georgia.

Borderline ovarian tumors (BOTs) represent particular challenge for diagnosis and clinical management as they are characterized with the features of both benign cystadenomas and malignant carcinomas. The aim of our study was to investigate histomorphological and immunohistochemical characteristics of ovarian serous-papillary borderline tumors, compared to serous cystadenomas and low- and high-grade serous carcinomas. Altogether, 80 formalin fixed and paraffin embedded tissue specimens, distributed in four groups, including serous cystadenoma (group I), serous BOTs (group II), Low (group III) and high (group IV) grade serous carcinomas, were investigated by standard immunohistochemistry, using antibodies against CK7 CK20, WT1, Vimentin, CDX2, CEA, ER, cyclin D1, BCL2, E-cadherin, calretinin, СA125, Ki67, P53. Study results showed, that ovarian serous BOTs are characterized with slightly increase proliferative potential compared to benign cystadenomas, whilst apoptotic potential is retained with the difference from malignant serous carcinomas. p53 mutation is not present, as well as the expression of Vimentin. Overall, ovarian serous BOTs are characterized with highly variable immunohistochemical phenotype and the use of multiple immunohistochemical markers are recommended for the differential diagnosis from low grade serous carcinomas and benign cystadenomas.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D060787 Neoplasm Grading Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm. Gleason Grading,Gleason Score,Tumor Grading,Grading, Gleason,Grading, Neoplasm,Grading, Tumor,Score, Gleason
D018284 Cystadenocarcinoma, Serous A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185) Cystadenocarcinomas, Serous,Serous Cystadenocarcinoma,Serous Cystadenocarcinomas
D018293 Cystadenoma, Serous A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972) Cystadenomas, Serous,Serous Cystadenoma,Serous Cystadenomas
D025721 WT1 Proteins Isoforms encoded by the WT1 Wilms tumor suppressor gene (GENES, WILMS TUMOR) and produced by alternative splicings. They are zinc finger-containing transcription factors involved in both transactivation and repression, and are critical for normal development and function of the urogenital tract. WT1 Gene Product,WT1 Protein,Gene Product, WT1,Protein, WT1,Proteins, WT1

Related Publications

V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
[Serous borderline ovarian tumors].
January 1985, Zentralblatt fur Gynakologie,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
The characteristics of ovarian serous tumors of borderline malignancy.
July 1980, Chinese medical journal,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
[Morphology of serous borderline ovarian tumors].
January 1989, Arkhiv patologii,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
[The characteristics of ovarian serous tumors of borderline malignancy (author's transl)].
January 1980, Zhonghua fu chan ke za zhi,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
What's new in ovarian serous borderline tumors.
January 1997, Pathology, research and practice,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
Ovarian serous borderline tumors: the citadel defended.
May 2000, Human pathology,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
Ovarian serous borderline tumors: the citadel defended.
November 2000, Human pathology,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
Fallopian tube correlates of ovarian serous borderline tumors.
December 2011, The American journal of surgical pathology,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
The molecular pathology of ovarian serous borderline tumors.
April 2016, Annals of oncology : official journal of the European Society for Medical Oncology,
V Munjishvili, and E Barabadze, and T Musashvili, and M Gachechiladze, and G Burkadze
Assessing the landscape of ovarian serous borderline tumors.
March 2019, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Copied contents to your clipboard!